Protalix BioTherapeutics (PLX) Short-term Investments (2020 - 2026)

Protalix BioTherapeutics has reported Short-term Investments for 7 years, with the latest figure at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 34.04% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $10.1 million (down 34.04% YoY), and the FY2025 full-year result was $15.6 million, up 3.47% from the prior year.
• Short-term Investments for Q1 2026 stood at $10.1 million, down from $15.6 million in the prior quarter.
• The five-year high for Short-term Investments was $21.6 million in Q2 2024, with the low at $5.1 million in Q4 2022.
• Average Short-term Investments over 5 years is $15.6 million, with a median of $15.7 million recorded in 2025.
• Year-over-year, Short-term Investments plunged 73.46% in 2022 and surged 312.82% in 2023.
• Tracing PLX's Short-term Investments over 5 years: stood at $5.1 million in 2022, then jumped by 312.82% to $20.9 million in 2023, then slipped by 27.98% to $15.1 million in 2024, then advanced by 3.47% to $15.6 million in 2025, then plunged by 35.34% to $10.1 million in 2026.
• The last three Short-term Investments figures came in at $10.1 million (Q1 2026), $15.6 million (Q4 2025), and $15.7 million (Q3 2025), per Business Quant data.

Peer Comparison